NURIX THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
NURIX THERAPEUTICS, INC. (NRIX) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $150.00 thousand as of 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2026-07-09
- 2026-05-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $150.00K.
- 2026-02-28: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $32.00K.
- 2025-11-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $10.00K.
- 2025-08-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $6.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2026-05-31 | $150.00K 10-Q · filed 2026-07-09 |
| 2026-02-28 | $32.00K 10-Q · filed 2026-04-08 |
| 2025-11-30 | $10.00K 10-Q · filed 2026-07-09 |
| 2025-08-31 | $6.00K 10-Q · filed 2025-10-09 |
| 2025-05-31 | $64.00K 10-Q · filed 2025-07-09 |
| 2025-02-28 | $40.00K 10-Q · filed 2025-04-08 |
| 2024-11-30 | $153.00K 10-K · filed 2026-01-28 |
| 2023-11-30 | $721.00K 10-K · filed 2025-01-28 |
| 2022-11-30 | $4.32M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |